Literature DB >> 2955070

Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.

F Cozzolino, M Torcia, A M Carossino, R Giordani, C Selli, G Talini, E Reali, A Novelli, V Pistoia, M Ferrarini.   

Abstract

The specific immune response against the malignant cells was investigated in patients with urinary bladder or larynx cancer. Lymphocytes from lymph nodes that drain the tumor site were tested for their proliferative and cytotoxic capacities against autologous malignant cells isolated from the primary tumor. In no occasion was a proliferative or a cytotoxic response observed. However, when the lymph node cell suspensions were depleted of cells expressing both OKM1 and Leu-7 markers by rosetting with the appropriate mAbs, a proliferative response could be observed. The lymphocytes responded to autologous tumor cells only if IL-2 was added to the cultures. IL-2 alone induced some cell proliferation, which was not, however, comparable to that observed in response to both IL-2 and tumor cells. A panel of allogeneic tumor cells consistently failed to stimulate OKM1-, Leu-7- cells in vitro. Response to autologous tumor cells was not caused by HLA-encoded molecules, as occurs in the autologous mixed lymphocyte reaction, since OKM1-, Leu-7- cells failed to be stimulated by autologous non-T cells. A proliferative response was observed only with cells from lymph nodes that had been classified as invaded by malignant cells according to histopathologic criteria. Cells from noninvaded lymph nodes consistently failed to respond. Cells stimulated with autologous tumor cells could be expanded in short-term lines by continuous addition of IL-2 and malignant cells. One of these lines, which comprised mainly T8+ cells, was stimulated to proliferate only by autologous tumor cells, and its proliferative response was inhibitable by anti-class I and not by anti-class II mAbs. This line showed lytic capacities against autologous malignant targets, while it was inefficient against all of the other allogeneic cells tested. In another set of experiments, the mechanisms whereby exogenous IL-2 had to be added to the cultures to sustain a proliferative response against neoplastic cells were investigated. When cocultured with autologous malignant cells, OKM1-, Leu-7- lymphocytes expressed IL-2 receptors, as could be assessed by anti-Tac fluorescent staining. Under these culture conditions, these cells did not produce IL-2, and no proliferation was observed. Addition of purified IL-1 to the cultures induced IL-2 production and cell proliferation. It is concluded that metastatic lymph nodes contain a T cell population that can be detected in a proliferative assay when both suppressor cells are removed and the appropriate molecular signals are supplied.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2955070      PMCID: PMC2189587          DOI: 10.1084/jem.166.2.303

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  45 in total

1.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

2.  Comparative study of membrane and intracytoplasmic immunoglobulin classes in human lymphoid cells.

Authors:  M Ferrarini; A Bargellesi; G Corte; G Viale; B Pernis
Journal:  Ann N Y Acad Sci       Date:  1975-06-30       Impact factor: 5.691

3.  A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

Authors:  T Uchiyama; S Broder; T A Waldmann
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

4.  A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1).

Authors:  T Abo; C M Balch
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

5.  Analysis of HLA-DR polymorphism by two-dimensional peptide mapping.

Authors:  G Corte; G Damiani; F Calabi; M Fabbi; A Bargellesi
Journal:  Proc Natl Acad Sci U S A       Date:  1981-01       Impact factor: 11.205

Review 6.  The differentiation and function of human T lymphocytes.

Authors:  E L Reinherz; S F Schlossman
Journal:  Cell       Date:  1980-04       Impact factor: 41.582

7.  Antigen-dependent proliferation of cloned continuous lines of H-2-restricted influenza virus-specific cytotoxic T lymphocytes.

Authors:  M E Andrew; T J Braciale
Journal:  J Immunol       Date:  1981-09       Impact factor: 5.422

8.  Ia antigen expression and IL-1 activity in murine tumour-associated macrophages.

Authors:  G Peri; V Rossi; G Taraboletti; A Erroi; A Mantovani
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

9.  Helper T cells for cytotoxic T lymphocytes need not be I region restricted.

Authors:  D H Raulet; M J Bevan
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307

10.  Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody.

Authors:  T Abo; M D Cooper; C M Balch
Journal:  J Exp Med       Date:  1982-01-01       Impact factor: 14.307

View more
  23 in total

1.  Tumour infiltrating lymphocytes: insights into tumour immunology and potential therapeutic implications.

Authors:  K F Yoong; D H Adams
Journal:  Clin Mol Pathol       Date:  1996-10

2.  Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors:  P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

3.  Tumor-infiltrating lymphocytes from nonrenal urological malignancies.

Authors:  G P Haas; D Solomon; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells.

Authors:  M Radrizzani; M Quaia; B Benedetti; S Andreola; M Vaglini; E Galligioni; G Fossati; G Parmiani
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Proliferative response of lymphocytes from ovarian cancer patients to autologous tumor cells.

Authors:  P Allavena; P Lo Presti; M Di Bello; V Lucchini; A Lissoni; G Zanetta; C Mangioni; A Mantovani
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

6.  Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro.

Authors:  P J Guillou; P C Sedman; C W Ramsden
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Coexpression of Fc gamma receptor IIIA and interleukin-2 receptor beta chain by a subset of human CD3+/CD8+/CD11b+ lymphocytes.

Authors:  S Zupo; L Azzoni; R Massara; A D'Amato; B Perussia; M Ferrarini
Journal:  J Clin Immunol       Date:  1993-05       Impact factor: 8.317

8.  Lymphokine production by human melanoma tumor-infiltrating lymphocytes.

Authors:  M A Salmeron; T Morita; H Seki; C D Platsoucas; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

9.  Activated T-cell subsets in benign lymphoid hyperplasias and B-cell non-Hodgkin's lymphomas.

Authors:  J I Diaz; M G Edinger; M H Stoler; R R Tubbs
Journal:  Am J Pathol       Date:  1991-09       Impact factor: 4.307

10.  Effect of interleukin-2 on the biodistribution of technetium-99m-labelled anti-CEA monoclonal antibody in mice bearing human tumour xenografts.

Authors:  K Nakamura; A Kubo
Journal:  Eur J Nucl Med       Date:  1994-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.